2 Information about pembrolizumab with lenvatinib

Marketing authorisation indication

2.1 Pembrolizumab (Keytruda, MSD), in combination with lenvatinib (Lenvima, Eisai), is indicated for 'the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab and lenvatinib.


2.3 The price of pembrolizumab is £2,630 per 100 mg per 4‑ml vial (excluding VAT; BNF online accessed October 2022). The price of lenvatinib is £1,437 per 30 4‑mg or 10‑mg capsules (excluding VAT; BNF online accessed October 2022). The companies have commercial arrangements. These make pembrolizumab and lenvatinib available to the NHS with discounts. The sizes of the discounts are commercial in confidence. It is the companies' responsibility to let relevant NHS organisations know details of the discounts.

  • National Institute for Health and Care Excellence (NICE)